Delivery Order SPE2DB22D9353-SPE2DB24FX1ZM

Award Date 6/21/24
Potential Completion Date 7/15/24
Potential Value $4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the delivery of OZURDEX 0.7 MG IMPLANTS. The contract has a potential value of $3,004.53 and a completion date of March 14, 2024. This delivery order contract is part of a larger indefinite delivery contract (Contract #4600082013) held by DMS Pharmaceutical Group Inc. with the DLA under the SPE2DB program, which has a ceiling value of up...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $3,004.53, is for the delivery of OZURDEX 0.7 MG IMPLANTS to support the recurring pharmaceutical supply needs of military health facilities. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued at up to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is valued at $4,006.04 and is for the delivery of OZURDEX 0.7 MG IMPLANTS to support the recurring medical supply needs of military health facilities. The contract has a period of performance through May 9, 2024 and does not have a set-aside designation. This delivery order contract is part of a...
The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract, valued at $2,003.02, is for the delivery of OZURDEX 0.7 MG IMPLANTS. This delivery order is part of a larger indefinite delivery contract, SPE2DB, held by DMS Pharmaceutical Group with the DLA, valued at up to $4,999,999 through the end of 2025. The contract has no set-aside...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $2,003.02 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the provision of OZURDEX 0.7 MG IMPLANTS, a specialized pharmaceutical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC covers a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,010.76 contract is for the delivery of OZURDEX 0.7 MG IMPLANTS to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group Inc. holds a $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of OZURDEX 0.7 MG IMPLANTS, with a potential value of $3,004.53 and a completion date of March 7, 2024. This delivery order is likely part of DMS Pharmaceutical Group's broader indefinite delivery contract with DLA, contract 4600082013 under the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The $2,003.02 contract is for the supply of OZURDEX 0.7 MG IMPLANTS, a pharmaceutical product, to support the recurring medical supply needs of military health facilities. The contract is part of DMS Pharmaceutical Group's broader indefinite delivery contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business based in Park Ridge, Illinois. The $2,003.02 contract is for the delivery of OZURDEX 0.7 MG IMPLANTS, a pharmaceutical product. This delivery order is placed against DMS Pharmaceutical Group's larger $4,999,999 indefinite delivery contract with DLA, which enables the agency to issue orders for a broad range of pharmaceutical...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has an award value of $3,016.14 and covers the delivery of OZURDEX 0.7 MG IMPLANTS, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. The contract is not associated with any set-aside designation, allowing DMS...
  • SPE2DB22D9353
    Indefinite Delivery Contract
  • SPE2DB22D9353-SPE2DB24FX1ZM
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $4,006.04 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of OZURDEX 0.7 MG IMPLANTS. This order was placed under DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, to provide a comprehensive range of pharmaceutical items in support of military health facilities worldwide. The contract has a period of performance through July 15, 2024 and was awarded on June 21, 2024 with no set-aside designation. As a prime vendor for the DLA's Medical Supply Chain division, DMS Pharmaceutical Group specializes in delivering a wide array of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to military and Veterans Affairs (VA) healthcare facilities.

Generated 9/20/24, 9:27 AM